Immunotherapy Combination Active in Advanced Melanoma

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.


Data from the KEYNOTE-001 study showed that the anti–PD-1 antibody pembrolizumab produces durable responses in metastatic melanoma patients.

Due to the genetic heterogeneity observed in tumors of melanoma patients who developed resistance to BRAF inhibitors, assessing mechanisms of resistance has minimal potential to inform further treatment decisions.

The anti–PD-1 antibody nivolumab alone or in combination with ipilimumab increased progression-free survival in treatment-naïve metastatic melanoma patients.

Performing a complete lymph node dissection does not improve survival for melanoma patients who underwent a sentinel node biopsy.

Researchers have identified several key diagnostic criteria for the diagnosis of melanoma and basal cell carcinoma with reflectance confocal microscopy.

Researchers have shown for the first time that an oncolytic immunotherapy can have therapeutic benefit in patients with advanced melanoma.

(Courtesy David Schwartz, MD)

There is a lot of new information about the link between various malignancies and inflammatory bowel disease. Here: answers to 3 key questions.


Subscribe to Melanoma on [sitename]
  • When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.

By clicking Accept, you agree to become a member of the UBM Medica Community.